Movement Alert｜Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains

Market Focus09:46

On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.

On the news front, multiple positive catalysts are converging. The company recently received CDE clinical trial acceptance for two Class 1 innovative drugs on the same day, accelerating its pipeline advancement. Meanwhile, China's National Healthcare Security Administration published 557 drugs passing basic medical insurance directory initial review and 54 drugs passing commercial insurance innovative drug directory initial review. The dual-directory negotiation mechanism combining public medical insurance and commercial insurance has entered a substantive phase, with an 8-year price protection mechanism simultaneously implemented. Market expectations for volume growth of high-clinical-value innovative drugs continue to strengthen.

Within the Biotechnology sector, peers also posted gains: REMEGEN up 3.64%, INNOVENT BIO up 3.36%, 3SBIO up 3.32%, SKB BIO up 1.6%, and AKESO up 1.07%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172971835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172971835","market":"us","top_or_hot":-1,"title":"Movement Alert｜Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains","media":"Market Focus","content":"<p><p>On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.</p><p>On the news front, multiple positive catalysts are converging. The company recently received CDE clinical trial acceptance for two Class 1 innovative drugs on the same day, accelerating its pipeline advancement. Meanwhile, China's National Healthcare Security Administration published 557 drugs passing basic medical insurance directory initial review and 54 drugs passing commercial insurance innovative drug directory initial review. The dual-directory negotiation mechanism combining public medical insurance and commercial insurance has entered a substantive phase, with an 8-year price protection mechanism simultaneously implemented. Market expectations for volume growth of high-clinical-value innovative drugs continue to strengthen.</p><p>Within the Biotechnology sector, peers also posted gains: REMEGEN up 3.64%, INNOVENT BIO up 3.36%, 3SBIO up 3.32%, SKB BIO up 1.6%, and AKESO up 1.07%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.</p><p>On the news front, multiple positive catalysts are converging. The company recently received CDE clinical trial acceptance for two Class 1 innovative drugs on the same day, accelerating its pipeline advancement. Meanwhile, China's National Healthcare Security Administration published 557 drugs passing basic medical insurance directory initial review and 54 drugs passing commercial insurance innovative drug directory initial review. The dual-directory negotiation mechanism combining public medical insurance and commercial insurance has entered a substantive phase, with an 8-year price protection mechanism simultaneously implemented. Market expectations for volume growth of high-clinical-value innovative drugs continue to strengthen.</p><p>Within the Biotechnology sector, peers also posted gains: REMEGEN up 3.64%, INNOVENT BIO up 3.36%, 3SBIO up 3.32%, SKB BIO up 1.6%, and AKESO up 1.07%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1172971835","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172971835","pubTimestamp":1783302389,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.On the news front,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"动静提示|康盟生物常规交易涨5.16%双保目录政策及两新药临床获批助推涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.On the news front, multiple positive catalysts are converging. The company recently received CDE clinical trial acceptance for two Class 1 innovative drugs on the same day, accelerating its pipeline advancement. Meanwhile, China's National Healthcare Security Administration published 557 drugs passing basic medical insurance directory initial review and 54 drugs passing commercial insurance innovative drug directory initial review. The dual-directory negotiation mechanism combining public medical insurance and commercial insurance has entered a substantive phase, with an 8-year price protection mechanism simultaneously implemented. Market expectations for volume growth of high-clinical-value innovative drugs continue to strengthen.Within the Biotechnology sector, peers also posted gains: REMEGEN up 3.64%, INNOVENT BIO up 3.36%, 3SBIO up 3.32%, SKB BIO up 1.6%, and AKESO up 1.07%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172971835","isCrawlerRequest":true}